CG Oncology (CGON) Revenue Quarterly: History & Chart

CG Oncology Inc.(CGON)

Biotechnology · Dallas, TX

$68.71+1.33 (+1.97%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About CG Oncology Inc.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

Dallas, TX

142 employees

cgoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Arthur Kuan

View full financials

Quarterly Revenue

Basis: latest reported fiscal quarter (Q2 FY2026). Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly revenue is $1.16M with QoQ Growth of +6.83%. Quarterly revenue is the total sales generated during the latest fiscal quarter.

Revenue TTM|Revenue Annual|Revenue CAGR|Financials

Quarterly Revenue

CGON Quarterly Revenue

$1.16M

Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $1.16M.

CGON P/S Ratio

Full P/S Ratio page

P/S Ratio

CGON P/S Ratio Chart

973.09

FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T12:06:04.725Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.

CGON EV/Sales

Full EV/Sales page

EV/Sales

CGON EV/Sales Chart

971.35x

Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T12:06:04.725Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.

Quarterly Revenue History

Period	Quarterly Revenue	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$1.16M	+6.83%	N/A
Q1 FY2026Period end 2026-03-31	$1.08M	(53.36%)	+1982.69%
Q4 FY2025Period end 2025-12-31	$2.32M	+39.38%	+409.21%
Q3 FY2025Period end 2025-09-30	$1.67M	N/A	N/A
Q2 FY2025Period end 2025-06-30	$0	(100.00%)	(100.00%)
Q1 FY2025Period end 2025-03-31	$52,000	(88.60%)	(90.17%)
Q4 FY2024Period end 2024-12-31	$456,000	N/A	N/A
Q3 FY2024Period end 2024-09-30	$43,000	(61.26%)	N/A
Q2 FY2024Period end 2024-06-30	$111,000	(79.02%)	N/A
Q1 FY2024Period end 2024-03-31	$529,000	N/A	+172.68%
Q4 FY2023Period end 2023-12-31	$1,000	N/A	N/A
Q3 FY2023Period end 2023-09-30	$9,000	N/A	N/A
Q2 FY2023Period end 2023-06-30	$0	(100.00%)	N/A
Q1 FY2023Period end 2023-03-31	$194,000	N/A	N/A
Q4 FY2022Period end 2022-12-31	$0	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.